TABLE 1.
The six-colour antibody panel used for flow-cytometric immunophenotyping of bone marrow (BM) aspirates
| Tube | FITC | PE | PerCP-Cy5,5 | APC | PE-Cy7 | APC-Cy7 | |
|---|---|---|---|---|---|---|---|
| 1. | mAb | κ | λ | CD19 | CD5 | CD10 | CD45 |
| Vé | 5 μl | 5 μl | 5 μl | 3 μl | 2 μl | 3 μl | |
| 2. | mAb | CD34 | CD117 | CD33 | HLA-DR | CD14 | CD45 |
| Vé | 3 μl | 3 μl | 2 μl | 2 μl | 3 μl | 3 μl | |
| 3. | mAb | CD3 | CD56 | CD5 | CD20 | CD19 | CD45 |
| Vé | 1 μl | 3 μl | 3 μl | 6 μl | 3 μl | 3 μl | |
| 4. | mAb | CD19 | CD45 | ||||
| Vé | 5 μl | 3 μl | |||||
| 5. | mAb | FMC7 | CD23 | CD19 | CD5 | CD10 | CD45 |
| Vé | 6 μl | 6 μl | 5 μl | 3μl | |||
| 6. | mAb | CD52 | CD11c | CD19 | CD38 | CD45 | |
| Vé | 3 μl | 5 μl | 5 μl | 3 μl | 3 μl | ||
| 7. | mAb | CD103 | CD22 | CD19 | CD25 | CD45 | |
| Vé | 5 μl | 4 μl | 5 μl | 2 μl | 3 μl | ||
| 8. | mAb | CD38 | CD56 | CD19 | CD138 | CD45 | |
| Vé | 5 μl | 3 μl | 5 μl | 5 μl | 3 μl | ||
| 9. | mAb | CD4 | CD8 | CD3 | CD7 | CD5 | CD45 |
| Vé | 3 μl | 4 μl | 3 μl | 2 μl | 5 μl | 3 μl | |
[i] APC = allophycocyanin; APC-Cy7 = allophycocyanin-cyanine 7; FITC = fluorescein isothiocyanate; mAb = monoclonal antibody; PE = phycoerythrin; PerCP-Cy5.5 = peridinin-chlorophyll-protein-complex-Cy5.5; PerCP = peridinin-chlorophyll-protein-complex; PE-Cy7 = phycoerythrin-cyanine7; V = volume; Vé = the volume of the antibodies was adjusted according to the results of titration measurements
TABLE 2.
Patients’ characteristics
| Age (median, range), years | 65 (20–79) | |
| Gender, female/male, n (%) | 64 (44.1%)/81 (55.9%) | |
| BMI − | BMI + | |
| Age (median) [years]; BMI−: BMI+ | 66 (25–79) | 63(20–78); p = 0.524 |
| Gender, female/male, n; | 48/54 | 16/27; p = 0.277 |
| IPI score, n (%) | ||
| IPI Low risk group (LR): 33 (22.8%) | 32 | 1 |
| IPI Low-intermediate risk group (LIR): 32 (22.1%) | 22 | 10 |
| IPI High-intermediate risk group (HIR): 33 (22.8%) | 24 | 9 |
| IPI High risk group (HR): 47 (32.4%) | 24 | 23 |
| Stage at diagnosis, n (%) | II: 39 (26.9%) | |
| III: 19 (13.1%) | ||
| IV: 87 (60.0%) | ||
| Chemotherapy regimen, n (%) | R-CHOP: 119 (82.1%) | |
| R-EPOCH: 9 (6.2%) | ||
| R-ACVBP: 6 (4.1%) | ||
| RCOEP: 3 (2.1%) | ||
| Other: 8 (5.5%) | ||
| Radiotherapy after chemotherapy, n (%) | 52 (35.9%) | |
| Death in 60 months follow-up period, n (%) | 29 (20.0%) | |
| Bone marrow involvements present-overall, n (%) | 43 (29.7%) | |
| Extranodal sites: 0, n (%) | 26 (17.9%) | |
| Extranodal sites: 1, n (%) | 48 (33.1%); of those BMI n = 11 (7.6%) | |
| Extranodal sites more than 1, no. (%) | 71 (49.0%) | |
[i] BMI = bone marrow involvement; IPI = international prognostic index; R-ACVBP = rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP); R-CEOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (a steroid) – (pred-ni-suh-lown); R-EPOCH = rituximab, etoposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin
FIGURE 1.
Overall survival.
FIGURE 2.
Gender based survival analysis.
FIGURE 3.
International prognostic index (IPI) survival analysis.
HR = high risk; HIR = high-intermediate risk; LIR = low-intermediate risk; LR = low risk
FIGURE 4.
Bone marrow involvement status survival analysis.
BM = bone marrow